综合级联抗氧化剂nanozymes-Cu5.4O@CNDs通过调节视黄醇代谢对抗急性肝损伤。

IF 12.4 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Theranostics Pub Date : 2025-04-21 eCollection Date: 2025-01-01 DOI:10.7150/thno.106811
Jiayu Chen, Yujie Zhang, Zhichao Deng, Yuanyuan Zhu, Chenxi Xu, Bowen Gao, Wenlong Wang, Jie Xiao, Zhengtao Xiao, Mingzhen Zhang, Kangsheng Tu
{"title":"综合级联抗氧化剂nanozymes-Cu5.4O@CNDs通过调节视黄醇代谢对抗急性肝损伤。","authors":"Jiayu Chen, Yujie Zhang, Zhichao Deng, Yuanyuan Zhu, Chenxi Xu, Bowen Gao, Wenlong Wang, Jie Xiao, Zhengtao Xiao, Mingzhen Zhang, Kangsheng Tu","doi":"10.7150/thno.106811","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Acute liver failure (ALF) represents a critical medical condition marked by the abrupt onset of hepatocyte damage, commonly induced by etiological factors such as hepatic ischemia/reperfusion injury (HIRI) and drug-induced hepatotoxicity. Across various types of liver injury, oxidative stress, heightened inflammatory responses, and dysregulated hepatic retinol metabolism are pivotal contributors, particularly in the context of excessive reactive oxygen species (ROS). <b>Methods:</b> C-dots were combined with Cu<sub>5.4</sub>O USNPs to synthesize a cost-effective nanozyme, Cu<sub>5.4</sub>O@CNDs, which mimics the activity of cascade enzymes. The <i>in vitro</i> evaluation demonstrated the ROS scavenging and anti-inflammatory capacity of Cu<sub>5.4</sub>O@CNDs. The therapeutic potential of Cu<sub>5.4</sub>O@CNDs was evaluated <i>in vivo</i> using mouse models of hepatic ischemia/reperfusion injury and LPS/D-GalN induced hepatitis, with transcriptome analysis conducted to clarify the mechanism underlying hepatoprotection. <b>Results:</b> The Cu<sub>5.4</sub>O@CNDs demonstrated superoxide dismutase (SOD) and catalase (CAT) enzyme activities, as well as hydroxyl radical (·OH) scavenging capabilities, effectively mitigating ROS <i>in vitro</i>. Furthermore, the Cu<sub>5.4</sub>O@CNDs exhibited remarkable targeting efficacy towards inflammation cells induced by H<sub>2</sub>O<sub>2</sub> and hepatic tissues in murine models of hepatitis, alongside exhibiting favorable biocompatibility in both <i>in vitro</i> and <i>in vivo</i> settings. Moreover, it has been demonstrated that Cu<sub>5.4</sub>O@CNDs effectively scavenged ROS, thereby enhancing cell survival <i>in vitro</i>. Additionally, Cu<sub>5.4</sub>O@CNDs exhibited significant therapeutic efficacy in mice models of HIRI and lipopolysaccharide-induced acute lung injury (LPS-ALI). This efficacy was achieved through the modulation of the ROS response and hepatic inflammatory network, as well as the amelioration of disruptions in hepatic retinol metabolism. <b>Conclusions:</b> In summary, this study demonstrates that Cu<sub>5.4</sub>O@CNDs exhibit significant potential for the treatment of various acute liver injury conditions, suggesting their promise as an intervention strategy for clinical application.</p>","PeriodicalId":22932,"journal":{"name":"Theranostics","volume":"15 12","pages":"5592-5615"},"PeriodicalIF":12.4000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068305/pdf/","citationCount":"0","resultStr":"{\"title\":\"Integrated cascade antioxidant nanozymes-Cu<sub>5.4</sub>O@CNDs combat acute liver injury by regulating retinol metabolism.\",\"authors\":\"Jiayu Chen, Yujie Zhang, Zhichao Deng, Yuanyuan Zhu, Chenxi Xu, Bowen Gao, Wenlong Wang, Jie Xiao, Zhengtao Xiao, Mingzhen Zhang, Kangsheng Tu\",\"doi\":\"10.7150/thno.106811\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Acute liver failure (ALF) represents a critical medical condition marked by the abrupt onset of hepatocyte damage, commonly induced by etiological factors such as hepatic ischemia/reperfusion injury (HIRI) and drug-induced hepatotoxicity. Across various types of liver injury, oxidative stress, heightened inflammatory responses, and dysregulated hepatic retinol metabolism are pivotal contributors, particularly in the context of excessive reactive oxygen species (ROS). <b>Methods:</b> C-dots were combined with Cu<sub>5.4</sub>O USNPs to synthesize a cost-effective nanozyme, Cu<sub>5.4</sub>O@CNDs, which mimics the activity of cascade enzymes. The <i>in vitro</i> evaluation demonstrated the ROS scavenging and anti-inflammatory capacity of Cu<sub>5.4</sub>O@CNDs. The therapeutic potential of Cu<sub>5.4</sub>O@CNDs was evaluated <i>in vivo</i> using mouse models of hepatic ischemia/reperfusion injury and LPS/D-GalN induced hepatitis, with transcriptome analysis conducted to clarify the mechanism underlying hepatoprotection. <b>Results:</b> The Cu<sub>5.4</sub>O@CNDs demonstrated superoxide dismutase (SOD) and catalase (CAT) enzyme activities, as well as hydroxyl radical (·OH) scavenging capabilities, effectively mitigating ROS <i>in vitro</i>. Furthermore, the Cu<sub>5.4</sub>O@CNDs exhibited remarkable targeting efficacy towards inflammation cells induced by H<sub>2</sub>O<sub>2</sub> and hepatic tissues in murine models of hepatitis, alongside exhibiting favorable biocompatibility in both <i>in vitro</i> and <i>in vivo</i> settings. Moreover, it has been demonstrated that Cu<sub>5.4</sub>O@CNDs effectively scavenged ROS, thereby enhancing cell survival <i>in vitro</i>. Additionally, Cu<sub>5.4</sub>O@CNDs exhibited significant therapeutic efficacy in mice models of HIRI and lipopolysaccharide-induced acute lung injury (LPS-ALI). This efficacy was achieved through the modulation of the ROS response and hepatic inflammatory network, as well as the amelioration of disruptions in hepatic retinol metabolism. <b>Conclusions:</b> In summary, this study demonstrates that Cu<sub>5.4</sub>O@CNDs exhibit significant potential for the treatment of various acute liver injury conditions, suggesting their promise as an intervention strategy for clinical application.</p>\",\"PeriodicalId\":22932,\"journal\":{\"name\":\"Theranostics\",\"volume\":\"15 12\",\"pages\":\"5592-5615\"},\"PeriodicalIF\":12.4000,\"publicationDate\":\"2025-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068305/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Theranostics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.7150/thno.106811\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Theranostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/thno.106811","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:急性肝衰竭(ALF)是一种以肝细胞突然损伤为特征的危重疾病,通常由肝缺血/再灌注损伤(HIRI)和药物性肝毒性等病因引起。在各种类型的肝损伤中,氧化应激、炎症反应加剧和肝视黄醇代谢失调是关键因素,特别是在活性氧(ROS)过量的情况下。方法:将C-dots与Cu5.4O USNPs结合,合成一种模拟级联酶活性的低成本纳米酶Cu5.4O@CNDs。体外评价表明Cu5.4O@CNDs具有清除ROS和抗炎能力。通过小鼠肝缺血/再灌注损伤模型和LPS/D-GalN诱导肝炎模型,在体内评估Cu5.4O@CNDs的治疗潜力,并进行转录组分析以阐明其保护肝脏的机制。结果:Cu5.4O@CNDs具有超氧化物歧化酶(SOD)和过氧化氢酶(CAT)活性,并具有清除羟基自由基(·OH)的能力,能有效减轻体外ROS。此外,Cu5.4O@CNDs在小鼠肝炎模型中对H2O2诱导的炎症细胞和肝组织具有显著的靶向作用,并且在体外和体内均表现出良好的生物相容性。此外,已经证明Cu5.4O@CNDs可以有效清除ROS,从而提高体外细胞存活率。此外,Cu5.4O@CNDs在HIRI和脂多糖诱导的急性肺损伤(LPS-ALI)小鼠模型中表现出显著的治疗效果。这种功效是通过调节ROS反应和肝脏炎症网络,以及改善肝视黄醇代谢的破坏来实现的。结论:总之,本研究表明Cu5.4O@CNDs在治疗各种急性肝损伤方面具有显著的潜力,这表明它们有望作为一种临床应用的干预策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Integrated cascade antioxidant nanozymes-Cu5.4O@CNDs combat acute liver injury by regulating retinol metabolism.

Background: Acute liver failure (ALF) represents a critical medical condition marked by the abrupt onset of hepatocyte damage, commonly induced by etiological factors such as hepatic ischemia/reperfusion injury (HIRI) and drug-induced hepatotoxicity. Across various types of liver injury, oxidative stress, heightened inflammatory responses, and dysregulated hepatic retinol metabolism are pivotal contributors, particularly in the context of excessive reactive oxygen species (ROS). Methods: C-dots were combined with Cu5.4O USNPs to synthesize a cost-effective nanozyme, Cu5.4O@CNDs, which mimics the activity of cascade enzymes. The in vitro evaluation demonstrated the ROS scavenging and anti-inflammatory capacity of Cu5.4O@CNDs. The therapeutic potential of Cu5.4O@CNDs was evaluated in vivo using mouse models of hepatic ischemia/reperfusion injury and LPS/D-GalN induced hepatitis, with transcriptome analysis conducted to clarify the mechanism underlying hepatoprotection. Results: The Cu5.4O@CNDs demonstrated superoxide dismutase (SOD) and catalase (CAT) enzyme activities, as well as hydroxyl radical (·OH) scavenging capabilities, effectively mitigating ROS in vitro. Furthermore, the Cu5.4O@CNDs exhibited remarkable targeting efficacy towards inflammation cells induced by H2O2 and hepatic tissues in murine models of hepatitis, alongside exhibiting favorable biocompatibility in both in vitro and in vivo settings. Moreover, it has been demonstrated that Cu5.4O@CNDs effectively scavenged ROS, thereby enhancing cell survival in vitro. Additionally, Cu5.4O@CNDs exhibited significant therapeutic efficacy in mice models of HIRI and lipopolysaccharide-induced acute lung injury (LPS-ALI). This efficacy was achieved through the modulation of the ROS response and hepatic inflammatory network, as well as the amelioration of disruptions in hepatic retinol metabolism. Conclusions: In summary, this study demonstrates that Cu5.4O@CNDs exhibit significant potential for the treatment of various acute liver injury conditions, suggesting their promise as an intervention strategy for clinical application.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Theranostics
Theranostics MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
25.40
自引率
1.60%
发文量
433
审稿时长
1 months
期刊介绍: Theranostics serves as a pivotal platform for the exchange of clinical and scientific insights within the diagnostic and therapeutic molecular and nanomedicine community, along with allied professions engaged in integrating molecular imaging and therapy. As a multidisciplinary journal, Theranostics showcases innovative research articles spanning fields such as in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensor technology, nanobiosensors, bioelectronics, system biology, translational medicine, point-of-care applications, and personalized medicine. Encouraging a broad spectrum of biomedical research with potential theranostic applications, the journal rigorously peer-reviews primary research, alongside publishing reviews, news, and commentary that aim to bridge the gap between the laboratory, clinic, and biotechnology industries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信